Journal article

What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial

Nicola J Lawrence, Andrew Martin, Ian D Davis, Simon Troon, Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Richard Kaplan, Benjamin Smith, Alastair Ritchie, Angela Meade, Tim Eisen, Prunella Blinman, Martin R Stockler

KIDNEY CANCER | IOS PRESS | Published : 2018


Background: Decisions about adjuvant therapy involve trade-offs between possible benefits and harms. Objective: We sought to determine the survival benefits that clinical investigators would judge as sufficient to warrant treatment with adjuvant sorafenib in the SORCE trial after nephrectomy for apparently localised renal cell carcinoma (RCC). Methods: A subset of clinical investigators in the SORCE trial completed a validated questionnaire that elicited the minimum survival benefits they judged sufficient to warrant one year of adjuvant sorafenib in scenarios with hypothetical baseline survival times of 5 years and 15 years, and baseline survival rates at 5 years of 65% and 85%. Results: Th..

View full abstract

University of Melbourne Researchers


Awarded by NHMRC Practitioner Fellowship

Awarded by Australian NHMRC Program Grant

Funding Acknowledgements

This work was supported by funding from Cancer Australia for ANZUP and the NHMRC Clinical Trials Centre. The SORCE trial was funded globally by Cancer Research UK, Bayer Pharmaceuticals and the Medical Research Council UK, and partly supported in Australia and New Zealand by an untied grant from Bayer Australia. Bayer had no input into the design, conduct, analysis, or reporting of this study. ID Davis is supported by an NHMRC Practitioner Fellowship (APP1102604). NJ Lawrence received support from an NHMRC Postgraduate Scholarship (Australia), Goldman Sachs NewZealand Fellowship (New Zealand) and a Top-Up PhD Scholarship from Sydney Catalyst (University of Sydney and Cancer Institute NSW, Australia).The NHMRC Clinical Trials Centre is supported by an Australian NHMRC Program Grant (APP1037786).